How We’ll Profit From 30 Years of Failure

If it ain’t broke, don’t fix it.

That’s the approach we’re going to take with our trading philosophy.

Markets are again trending green today, and on the year all the major averages are up considerably.


Our tech and biotech plays are no different.

Take for instance the iShares Nasdaq Biotech ETF (IBB) and the SPDR Technology Select Sector ETF (XLK) below.


Both funds are edging out the best-performing major average. I expect this to continue through 2019.

Especially in biotech.

We have a ton of opportunity on hand with a potential record number of new drug trials this year.

New drugs = new revenue.

And even if only a handful of these drug make it through the FDA gauntlet, we’ll rake in tons of cash with targeted moves.

But the first step we need to take is weeding out the losers so that we can focus on the winners for max profits.

Let’s get started.

Another One Bites the Dust!

It’s an all-too-common story for biotechs trying to cure Alzheimer’s disease.

Despite hundreds of attempts at finding a therapy that can at least slow down AD, we’ve got nothing to show for it but four approved therapies.

None of which addresses the root cause of this increasingly common neurodegenerative condition. All existing therapies only mask the progression of this dreadful disease.

The latest to end up on the cutting floor was a therapy called crenezumab. Crenezumab was under development at Roche and Genentech, and the companies threw in the towel during a recent Phase 3 trial.

Biotechs and Big Pharmas alike have failed again and again to cure Alzheimer’s. It seems many researchers still don’t fundamentally understand this disease yet.

The mainstream theory is that Alzheimer’s is caused by the buildup of beta amyloid proteins in the brain into large deposits that are the cause of AD.

These deposits, also called plaques, have been a physiological hallmark ever since Alois Alzheimer autopsied brains of people who died with this form of dementia.

Crenezumab was supposed to work in accordance with the mainstream theory.

Clear out the plaques and you stop the progression of Alzheimer’s.

But crenezumab’s failure indicates there’s more to curing Alzheimer’s than just clearing out these plaque deposits.

Profiting Off Failure

There’s one company using what was learned from crenezumab’s failure.

This company’s scientists have identified that it isn’t garden-variety amyloid proteins that are the problem.

Specifically, they’re mutated, twisted, misfolded, toxic variants. According to this idea, misfolded proteins act like prions, meaning they essentially “infect” normal forms of beta amyloid, turning them into toxic versions as well.

To that end, this company is developing highly specific, targeted therapies based on monoclonal antibodies engineered in a lab.

They are working on engineered antibodies that target these misfolded variants specifically, tagging them for immune system clearance.

This specificity should allow for higher dosing and greater clearance of toxic species of this protein.

If it works, it will be a historic victory.

As such, I’m tracking this company’s trial data very, very closely. I’ve also started compiling all the info I have right here.

Curing Alzheimer’s could be right around the corner.

For Technology Profits Daily,

Ray Blanco
Chief Technology Expert, Technology Profits Daily

You May Also Be Interested In:

Ray Blanco

Ray Blanco is the editor of Technology Profits Confidential as well as Breakthrough Technology Alert, FDA Profit Alert, and Technology Profits Daily. Ray has been with Seven Figure Publishing since 2010. In 2019, his closed positions in Technology Profits Confidential outperformed the S&P500 by 50%.

View More By Ray Blanco